Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intest...
| Publicado en: | Digestive Diseases & Sciences Vol. 63; no. 4; pp. 825 - 834 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Apr2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |